Dr. Priya Nandakumar brings scientific and clinical insight to The Catalyst Brief’s coverage of biomedical research and healthcare innovation. Her work bridges experimental findings, clinical data, and industry strategy, helping readers interpret what new evidence means beyond the lab or trial setting. At The Catalyst Brief, Priya emphasizes translational relevance and long-term implications for patients and pipelines.
160 articlesMostly Regulatory & Policy and Biopharmaceutical Industry
Healthcare InvestmentMedicare Advantage, a key segment in the healthcare insurance landscape, has experienced dwindling membership growth as several leading insurers, including UnitedHealth, Humana, and Aetna, have been actively reducing their rolls. This development follows a series of changes affecting the program and could signal a major shift in the sector.
Dr. Priya NandakumarFeb 16, 2026
Regulatory & PolicyMedicaid funding has become a contentious political issue in the United States as the Trump administration implements significant budget reductions. This approach has pitted states with large urban populations against those with predominantly rural demographics, exposing the complex dynamics of healthcare policy across different geographic regions. Key stakeholders are debating the implications for healthcare access and equity.
Dr. Priya NandakumarFeb 11, 2026
Regulatory & PolicyThe refusal by the Food and Drug Administration to review Moderna's influenza vaccine application marks a significant regulatory event. This decision has generated discussion among industry stakeholders about the future direction and posture of the FDA toward vaccines and pharmaceutical approvals generally.
Dr. Priya NandakumarFeb 11, 2026
Regulatory & PolicyRegenxbio, a prominent biotech firm specializing in gene therapy, received a setback as the FDA rejected its application for a rare-disease treatment. This decision reflects the stringent standards and challenges that gene therapies encounter in securing regulatory approval, especially in rare disease indications.
Dr. Priya NandakumarFeb 10, 2026
Regulatory & PolicyThe ethics of gender-affirming care for minors has become a contentious issue following a Health and Human Services report. Critics argue about the use of scare tactics in recent commentaries, raising important questions about medical ethics, patient well-being, and public policy.
Dr. Priya NandakumarFeb 7, 2026
Healthcare InvestmentPrimeGen’s decision to go public via a Special Purpose Acquisition Company (SPAC) represents an important step in the evolving regenerative medicine landscape. This strategic move not only provides capital for advancing a promising pre-clinical stem cell pipeline but also highlights growing investor interest in transformative cell therapies targeting unmet medical needs.
Dr. Priya NandakumarFeb 5, 2026
Healthcare InvestmentThe year 2021 marked an unprecedented wave of biotech initial public offerings, heavily influenced by pandemic-related funding surges. This article analyzes where these companies stand today, their challenges, and implications for future biotech investment landscapes.
Dr. Priya NandakumarFeb 4, 2026
AI in Drug DiscoveryAs artificial intelligence technology continues to permeate healthcare, Alaffia Health is positioning itself to address the increasing need for efficiency among payers. By leveraging clinically informed AI to streamline administrative operations and reduce waste within healthcare claims, the company recently secured $55 million in investment to accelerate its platform's development and adoption. This funding milestone highlights the growing recognition of AI's role beyond providers and into payer organizations that face pressures to modernize systems and improve operational outcomes.
Dr. Priya NandakumarFeb 4, 2026
Healthcare InvestmentThe biotech sector is encountering a notably active week for IPOs with four companies navigating toward public listings despite governmental operational interruptions. This development illustrates both market demand for innovative healthcare solutions and the strategic approaches companies adopt to overcome regulatory obstacles in pursuit of capital markets.
Dr. Priya NandakumarFeb 3, 2026
Medical TechnologyDextrocardia is a rare congenital condition characterized by the heart and organs being reversed from their usual position. While rare, congenital heart defects are common and can vary in severity and impact. This article discusses the clinical perspectives on dextrocardia, its epidemiology, and implications for health.
Dr. Priya NandakumarFeb 3, 2026
Healthcare InvestmentThis merger brings together two major players in the healthcare industry to offer integrated primary care, behavioral health, pharmacy services, and care navigation designed for large self-insured employers. It signals a shift toward more comprehensive, scalable employer health solutions.
Dr. Priya NandakumarFeb 1, 2026
Regulatory & PolicyHealth Secretary Robert F. Kennedy Jr. indicated in a recent Cabinet meeting that the TrumpRx website might go live within approximately ten days, yet clarity on the exact launch date remains elusive amid scrutiny over regulatory compliance.
Dr. Priya NandakumarJan 30, 2026